This Is AuburnElectronic Theses and Dissertations

Show simple item record

Disposition of levetiracetam in healthy adult horses


Metadata FieldValueLanguage
dc.contributor.advisorStewart, Allison
dc.contributor.advisorBoothe, Dawn
dc.contributor.advisorRavis, William R.
dc.contributor.advisorDuran, Sue
dc.contributor.advisorWooldridge, Anne
dc.contributor.advisorRobyn, Wilborn
dc.contributor.authorCesar, Fernanda
dc.date.accessioned2014-07-11T15:14:47Z
dc.date.available2014-07-11T15:14:47Z
dc.date.issued2014-07-11
dc.identifier.urihttp://hdl.handle.net/10415/4258
dc.description.abstractNine horses received 20 mg/kg of intravenous LEV (LEVIV), 30 mg/kg of intragastric, immediate release LEV (LEVIR) and extended release (LEVER), in a 3-way randomized crossover design. Serum samples were collected over 48 hours, and LEV concentrations determined by immunoassay. Mean  SEM peak concentrations for LEVIR and LEVER were 50.72  3.53 and 53.58  5.31 g/mL, respectively. The mean y-intercept for IV administration was 64.54  8.33 g/mL. The terminal half-life was 6.38  1.97, 7.07  1.93 and 6.22  1.35 hours for LEVIR, LEVER and LEVIV, respectively. Volume of distribution at steady state was 0.63  0.02 L/kg. Total body clearance after IV administration was 1.24  0.10 ml/kg/min. Bioavailability was excellent. Based on this study, a recommended dosing regimen of intravenous or oral LEV, of 32 mg/kg every 12 hours is likely to achieve and maintain therapeutic range with optimal kinetics throughout dosing interval.en_US
dc.rightsEMBARGO_NOT_AUBURNen_US
dc.subjectBiomedical Sciencesen_US
dc.titleDisposition of levetiracetam in healthy adult horsesen_US
dc.typethesisen_US
dc.embargo.lengthNO_RESTRICTIONen_US
dc.embargo.statusNOT_EMBARGOEDen_US

Files in this item

Show simple item record